Cutia Therapeutics (HKSE:02487) Equity-to-Asset : 0.90 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cutia Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$1,768.0 Mil. Cutia Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was HK$1,956.6 Mil. Therefore, Cutia Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.90.

The historical rank and industry rank for Cutia Therapeutics's Equity-to-Asset or its related term are showing as below:

HKSE:02487' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.86 Med: -0.53 Max: 0.9
Current: 0.79

During the past 3 years, the highest Equity to Asset Ratio of Cutia Therapeutics was 0.90. The lowest was -0.86. And the median was -0.53.

HKSE:02487's Equity-to-Asset is ranked better than
65.62% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02487: 0.79

Cutia Therapeutics Equity-to-Asset Historical Data

The historical data trend for Cutia Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Equity-to-Asset Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

-0.53

-0.86

0.79

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	-0.53	-	-0.86	0.90	0.79

Competitive Comparison of Cutia Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Cutia Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cutia Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Equity-to-Asset falls into.

Cutia Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cutia Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-1391.779	/	1615.668
	=	-0.86

Cutia Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1767.992	/	1956.596
	=	0.90

Cutia Therapeutics (HKSE:02487) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cutia Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics (HKSE:02487) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.

Executives

Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hsg Holding Limited	2201 Interest of corporation controlled by you
Ma Yun	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Aurora Cutis Limited	2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines